Pricing Log in Create free account
Friday 6 November 2026 Export EXEL’s income statement to Excel — free account

Exelixis, Inc.

EXEL Healthcare Biotechnology

Exelixis, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.3 billion, up 6.98% from fiscal 2024.

Revenue
+10.2%
EPS
+22.2%
Free cash flow
−4.83%

Quarter to September 2026, against a year earlier

69.74 1.03 +1.50%
Market cap
$16.8B
P/E
19.9×
Fwd P/E
20.2×
Dividend yield
—
F-score
7/9
Altman Z
12.68
Beneish M
−2.61
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Exelixis, Inc. 8-K filed May 13, 2025

Period ended May 13, 2025 · Filed · accepted 4:10 PM ET · Document on sec.gov · Filing index

2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits

Nothing in this filing raised a red flag, and we have no summary of it. The items it reports are listed above; the document itself is on sec.gov.

Read the filing on sec.gov The press release